Jeffrey Scott Cole - 23 Jan 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Role
Chief Operating Officer
Signature
/s/ Matthew K. Szot, Attorney-in-fact
Issuer symbol
CVKD
Transactions as of
23 Jan 2025
Net transactions value
$0
Form type
4
Filing time
24 Jan 2025, 18:11:37 UTC
Previous filing
03 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVKD Stock Options Award $0 +25,000 $0.000000 25,000 23 Jan 2025 Common Stock 25,000 $19.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of options to purchase 25,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.